OTCMLOBEF
Market cap2mUSD
Jan 14, Last price
0.02USD
1D
10.59%
1Q
39.26%
IPO
-76.50%
Name
Lobe Sciences Ltd
Chart & Performance
P/E
—
P/S
4.90
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
169.51%
Rev. gr., 5y
4.55%
Revenues
841k
Net income
-5m
L-61.58%
CFO
-2m
L-37.06%
Earnings
Feb 13, 2025
Profile
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑08 | 2022‑08 | 2021‑08 | 2020‑08 | 2019‑08 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||
Revenues | 841 | |||||||
Cost of revenue | 4,156 | 4,123 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (3,316) | (4,123) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 205 | 5,490 | ||||||
Tax Rate | ||||||||
NOPAT | (3,521) | (9,614) | ||||||
Net income | (4,707) -61.58% | (12,253) 26.86% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 676 | 753 | ||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 333 | |||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 192 | (1,590) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (1,719) | (2,731) | ||||||
CAPEX | ||||||||
Cash from investing activities | 1,743 | |||||||
Cash from financing activities | 950 | 753 | ||||||
FCF | (2,184) | (7,909) | ||||||
| Balance | ||||||||
Cash | 140 | 908 | ||||||
Long term investments | 682 | |||||||
Excess cash | 98 | 1,590 | ||||||
Stockholders' equity | (8,060) | 446 | ||||||
Invested Capital | 8,232 | |||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 104,351 | 37,862 | ||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (3,272) | (4,113) | ||||||
EV/EBITDA | ||||||||
Interest | 39 | |||||||
Interest/NOPBT | ||||||||